Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy
Sign Up to like & getrecommendations! Published in 2022 at "World Journal of Urology"
DOI: 10.1007/s00345-022-03963-y
Abstract: This study investigated the impact of treatment intensification with upfront docetaxel (DOC) or abiraterone (ABI) plus prednisolone on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) by comparing it with androgen deprivation therapy… read more here.
Keywords: high volume; doc; upfront abi; upfront doc ... See more keywords